Publicações

Phase 3 Sophia Study of Margetuximab plus Chemotherapy Vs Trastuzumab plus Chemotherapy in Patients with Her2+Metastatic Breast Cancer After Prior Anti-Her2 Therapies: Second Interim Overall Survival Analysis

AuthID
P-00S-87X

Author(s)

Rugo, HS

Im, SA

Cardoso, F

Cortes, J

Curigliano, G

Pegram, MD

Musolino, A

Bachelot, T

Wright, GS

De laurentiis, M

Kaufman, PA

Pluard, T

Ricci, F

Salazar, LG

Yardley, DA

Edlich, S

Hong, SY

Rock, E

Gradishar, WJ

Group Author(s)

SOPHIA Study Grp

Tipo de Documento

Abstract

Year published

2020

Publicado

in CANCER RESEARCH, ISSN: 0008-5472

Volume: 80, Número: 4

Conference

San Antonio Breast Cancer Symposium, Date: DEC 10-14, 2019, Location: San Antonio, TX

Indexing

Wos^®

Google Scholar^®

Metadata
Fontes

Publication Identifiers

DOI: 10.1158/1538-7445.sabcs19-gs1-02

Wos: WOS:000527012500025

Source Identifiers

ISSN: 0008-5472

Export Publication Metadata

Lista Marked

Adicionar à lista Marked

Info

At this moment we don't have any links to full text documens.

Phase 3 Sophia Study of Margetuximab plus Chemotherapy Vs Trastuzumab plus Chemotherapy in Patients with Her2+Metastatic Breast Cancer After Prior Anti-Her2 Therapies: Second Interim Overall Survival Analysis

Links Úteis

Ajuda

Autenticação Federada (Clique na imagem)

Phase 3 Sophia Study of Margetuximab plus Chemotherapy Vs Trastuzumab plus Chemotherapy in Patients with Her2+Metastatic Breast Cancer After Prior Anti-Her2 Therapies: Second Interim Overall Survival Analysis

Links Úteis

Ajuda